Edition:
United States

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

150.28USD
19 Jul 2018
Change (% chg)

$0.47 (+0.31%)
Prev Close
$149.81
Open
$149.76
Day's High
$151.53
Day's Low
$149.76
Volume
155,441
Avg. Vol
332,573
52-wk High
$155.16
52-wk Low
$100.20

Chart for

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $31,576.82
Shares Outstanding(Mil.): 210.78
Dividend: --
Yield (%): --

Financials

  EW.N Industry Sector
P/E (TTM): 38.00 37.62 32.86
EPS (TTM): 3.95 -- --
ROI: 19.43 8.77 13.13
ROE: 28.25 12.59 15.07

BRIEF-Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards Sapien 3 Valve

* REAL-WORLD EVIDENCE CONFIRMS CLINICAL TRIAL OUTCOMES FOR PATIENTS TREATED WITH EDWARDS SAPIEN 3 VALVE

May 22 2018

BRIEF-Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

* EDWARDS LIFESCIENCES ENTERS INTO ACCELERATED SHARE REPURCHASE AGREEMENT

May 01 2018

BRIEF-Edwards Lifesciences Says Entered Into Credit Agreement To Establish Multi-Currency Unsecured Revolving Credit Facility - SEC Filing

* EDWARDS LIFESCIENCES SAYS ENTERED INTO CREDIT AGREEMENT TO ESTABLISH NEW 5-YEAR $750 MILLION MULTI-CURRENCY UNSECURED REVOLVING CREDIT FACILITY - SEC FILING

Apr 30 2018

BRIEF-Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

* EDWARDS GRANTED CE MARK FOR FIRST TRANSCATHETER TRICUSPID THERAPY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc .

Apr 24 2018

UPDATE 2-Edward Lifesciences' heart valve sales in Europe disappoint, shares fall

April 24 Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc.

Apr 24 2018

BRIEF-Edwards Lifesciences Reports Q1 Earnings Of $0.96/Share

* QUARTERLY TOTAL ADJUSTED SALES $937.5 MILLION, UP 9.3 PERCENT

Apr 24 2018

Edwards Lifesciences reports 1.3 pct rise in quarterly sales

April 24 Medical device maker Edwards Lifesciences Corp reported a 1.3 percent rise in first-quarter revenue on Tuesday on higher demand for transcatheter heart valves, its biggest business.

Apr 24 2018

BRIEF-Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

* BOSTON SCIENTIFIC PREVAILS IN EUROPEAN PATENT DISPUTE WITH EDWARDS LIFESCIENCES

Apr 16 2018

BRIEF-Edwards Lifesciences Corp Says CEO Michael Mussallem's FY 2017 Total Compensation Was $10.8 Mln Vs $9.7 Mln In FY 2016

* EDWARDS LIFESCIENCES CORP SAYS CEO MICHAEL MUSSALLEM'S FY 2017 TOTAL COMPENSATION WAS $10.8 MILLION VERSUS $9.7 MILLION IN FY 2016 - SEC FILING Source text: (https://bit.ly/2GUuNcF) Further company coverage:

Mar 29 2018

Earnings vs. Estimates